{"id":"depocyte","safety":{"commonSideEffects":[{"rate":null,"effect":"Arachnoiditis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL803","moleculeType":"Small molecule","molecularWeight":"243.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DepoCyte is liposomal cytarabine designed for intrathecal administration, providing prolonged drug exposure in the cerebrospinal fluid. The liposomal formulation allows for extended release of cytarabine, reducing the frequency of intrathecal injections compared to conventional cytarabine while maintaining cytotoxic activity against leukemic cells in the CNS.","oneSentence":"DepoCyte is a sustained-release formulation of cytarabine that delivers chemotherapy directly into the cerebrospinal fluid to treat hematologic malignancies affecting the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:13.321Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphomatous meningitis"},{"name":"Leukemic meningitis"}]},"trialDetails":[{"nctId":"NCT02393157","phase":"PHASE2","title":"Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2015-08-21","conditions":"Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":25},{"nctId":"NCT00945724","phase":"PHASE2","title":"Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-09-27","conditions":"Large B-cell Diffuse Lymphoma of Testis","enrollment":54},{"nctId":"NCT00801216","phase":"PHASE2","title":"High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement","status":"COMPLETED","sponsor":"Andrés José Maria Ferreri","startDate":"2007-01","conditions":"B-cell Lymphomas","enrollment":40},{"nctId":"NCT00198978","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-01","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":377},{"nctId":"NCT01458730","phase":"PHASE2","title":"Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-05","conditions":"Central Nervous System Lymphoma","enrollment":66},{"nctId":"NCT01325194","phase":"PHASE2","title":"CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis","status":"COMPLETED","sponsor":"Nordic Lymphoma Group","startDate":"2011-03","conditions":"Primary Disease","enrollment":143},{"nctId":"NCT01645839","phase":"PHASE3","title":"Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2011-08-30","conditions":"Breast Cancer, Leptomeningeal Metastases","enrollment":74},{"nctId":"NCT00553943","phase":"PHASE2","title":"Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2007-07","conditions":"Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma","enrollment":60},{"nctId":"NCT00073957","phase":"PHASE2","title":"Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2003-12","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT00992602","phase":"PHASE2","title":"Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2011-04","conditions":"Central Nervous System Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer","enrollment":3},{"nctId":"NCT01653067","phase":"PHASE2","title":"STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Mathias Witzens-Harig","startDate":"2012-09","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":88},{"nctId":"NCT00944008","phase":"PHASE3","title":"PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"PETHEMA Foundation","startDate":"2009-09","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT00795756","phase":"PHASE2, PHASE3","title":"Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Northern Italy Leukemia Group","startDate":"2008-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":145},{"nctId":"NCT00854867","phase":"PHASE1","title":"Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2011-02","conditions":"Solid Tumour Neoplastic Meningitis, Brain Metastases","enrollment":18},{"nctId":"NCT00991744","phase":"PHASE3","title":"Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)","status":"SUSPENDED","sponsor":"Nordic Society for Pediatric Hematology and Oncology","startDate":"2009-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT00388531","phase":"PHASE2","title":"Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Lymphoblastic Leukemia, Lymphoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[{"count":18,"reaction":"HEADACHE"},{"count":17,"reaction":"PYREXIA"},{"count":12,"reaction":"DEAFNESS"},{"count":11,"reaction":"ARACHNOIDITIS"},{"count":11,"reaction":"GRANULOMATOUS LIVER DISEASE"},{"count":10,"reaction":"FEBRILE NEUTROPENIA"},{"count":10,"reaction":"THROMBOCYTOPENIA"},{"count":8,"reaction":"CONFUSIONAL STATE"},{"count":8,"reaction":"OFF LABEL USE"},{"count":7,"reaction":"HAEMATOTOXICITY"}],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DepoCyte","genericName":"DepoCyte","companyName":"PETHEMA Foundation","companyId":"pethema-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DepoCyte is a sustained-release formulation of cytarabine that delivers chemotherapy directly into the cerebrospinal fluid to treat hematologic malignancies affecting the central nervous system. Used for Lymphomatous meningitis, Leukemic meningitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}